Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Other 1

Conditions

Obesity 3Endometrial Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Opioid-Related Disorders 1Lymphoma, Follicular 1Hyperplasia 1Endometrial Hyperplasia 1

Interventions

pembrolizumab 14Paclitaxel 13Carboplatin 12Bevacizumab 7Specimen Handling 6Cisplatin 6olaparib 5Taxes 5Fulvestrant 5Nivolumab 4Megestrol Acetate 4Magnetic Resonance Spectroscopy 4Biopsy 4palbociclib 3durvalumab 3Oxaliplatin 3Leucovorin 3Letrozole 3Immunoglobulin G 3Fluorouracil 3Doxorubicin 3Docetaxel 3Disulfides 3trastuzumab deruxtecan 2ribociclib 2pertuzumab 2lenvatinib 2ipatasertib 2dostarlimab 2capivasertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Tirzepatide × 30 days × Clear all
NCT07078838 2026-06-04

Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer

UNC Lineberger Comprehensive Cancer Center

Phase 2 Not yet recruiting
40 enrolled
GynecologicOther

Endometrial Hyperplasia, Hyperplasia, Obesity, Endometrial Neoplasms

NCT07605247 2026-05-22

TREAT-EC

Rutgers, The State University of New Jersey

Phase 2 Not yet recruiting
30 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡